Incremental Yield of Artificial Intelligence in a Fecal Occult Blood Test Based Organized Screening Population Program

Pesatori, Eugenia V.; Milluzzo, Sebastian Manuel; Cesaro, Paola; Mussetto, Alessandro; Catino, F.; Quadarella, Alessandro; Olivari, N; Grazioli, Leonardo Minelli; Codazzi, Manuela; Bizzotto, Alessandra; Hassan, Cesare; Spada, Cristiano

doi:10.1016/j.gie.2022.04.639

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a randomized study with 800 patients, the CAD EYE (Fujifilm, Tokyo, Japan) CADe system was assessed within a fecal immunochemical test-based colorectal screening setting and was found to significantly increase ADR (45.3 % vs. 53.6 %) and APC (0.90 vs. 1.13; P = 0.028) [14]. In another randomized study evaluating AI-assisted colonoscopy, a significant improvement in PDR and ADR was observed [15]. Although CADe systems may on the surface appear to be similar in terms of their outputs, difference in underlying AI algorithms between devices may contribute to variation in findings between studies.…”

Section: Outcomementioning

confidence: 99%

“…Several studies have assessed the use of alternative CADe systems within a screening setting but have not incorporated the use of Endocuff Vision [13][14][15]. Shaukat et al assessed the SKOUT CADe device (Iterative Scopes, Cambridge, Massachusetts, USA) in a randomized study with 1359 patients included in the analysis, and showed a significant improvement in APC when using CADe (0.83 vs. 1.05; P = 0.002) for screening and surveillance colonoscopies [13].…”

Section: Outcomementioning

confidence: 99%

See 1 more Smart Citation

Evaluation of a real-time computer-aided polyp detection system during screening colonoscopy: AI-DETECT study

et al. 2022

View full text Add to dashboard Cite

Background Polyp detection and resection during colonoscopy significantly reduce long-term colorectal cancer risk. Computer-aided detection (CADe) may increase polyp identification but has undergone limited clinical evaluation. Our aim was to assess the effectiveness of CADe at colonoscopy within a bowel cancer screening program (BCSP). Methods This prospective, randomized controlled trial involved all eight screening-accredited colonoscopists at an English National Health Service (NHS) BCSP center (February 2020 to December 2021). Patients were randomized to CADe or standard colonoscopy. Patients meeting NHS criteria for bowel cancer screening were included. The primary outcome of interest was polyp detection rate (PDR). Results 658 patients were invited and 44 were excluded. A total of 614 patients were randomized to CADe (n = 308) or standard colonoscopy (n = 306); 35 cases were excluded from the per-protocol analysis due to poor bowel preparation (n = 10), an incomplete procedure (n = 24), or a data issue (n = 1). Endocuff Vision was frequently used and evenly distributed (71.7 % CADe and 69.2 % standard). On intention-to-treat (ITT) analysis, there was a borderline significant difference in PDR (85.7 % vs. 79.7 %; P = 0.05) but no significant difference in adenoma detection rate (ADR; 71.4 % vs. 65.0 %; P = 0.09) for CADe vs. standard groups, respectively. On per-protocol analysis, no significant difference was observed in these rates. There was no significant difference in procedure times. Conclusions In high-performing colonoscopists in a BCSP who routinely used Endocuff Vision, CADe improved PDR but not ADR. CADe appeared to have limited benefit in a BCSP setting where procedures are performed by experienced colonoscopists.

show abstract

Section: Outcomementioning

confidence: 99%